IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4333
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$90M
Miranda J. Toledano
Entera Bio Ltd. focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ENTX Entera Bio Ltd. | 33 | 24 | 38 | 18 | 22.6x | - | -75.1% | -65.7% | 0.0% | -6647.6% | -6652.4% | -100.0% | 0.0% | 14.0x | $90M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Entera Bio Ltd. (ENTX) receives a "Avoid" rating with a composite score of 32.5/100. It ranks #4333 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ENTX.
View All RatingsROE proxy -75.1% (sector -1.9%)
GM 0% vs sector 44%, OM -6648% vs sector 3%
Capital turnover N/A
Rev growth -100%, 8yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Entera Bio Ltd. (ENTX) as Avoid with a composite score of 32.5/100 at a current price of $1.55. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Entera Bio Ltd. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.5/100 places it at rank #4333 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Entera Bio Ltd. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Entera Bio Ltd. with an Avoid rating, assigning a composite score of 32.5/100 and 1 out of 5 stars. Ranked #4333 of 7,333 stocks, ENTX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Entera Bio Ltd. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -75.1% (sector avg: -1.9%), gross margins of 0.0% (sector avg: 44.1%), net margins of -6652.4% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 38/100, ENTX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 22.57x, a P/B ratio of 4.42x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Entera Bio Ltd.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 6.7% and a return on assets of -65.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Entera Bio Ltd. is experiencing notably weak momentum with a score of just 18/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -100.0% year-over-year, while a beta of 0.44 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 46/100, ENTX exhibits average financial resilience. Key stability metrics include a beta of 0.44 and a debt-to-equity ratio of 14.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
ENTX carries a short interest score of 70/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 14.00x), micro-cap liquidity risk. At $90M market cap (micro-cap), Entera Bio Ltd. offers reasonable institutional liquidity.
Entera Bio Ltd. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4333 of 7,333 overall (41st percentile). Key comparisons include ROE of -75.1% trailing the -1.9% sector median and operating margins of -6647.6% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ENTX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (18) would have the largest impact on the composite score.
ROE 3854% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 100% BELOW SECTOR MEDIAN
Op. Margin 264945% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s Chief Executive Officer, Miranda Toledano, in December 2025. The purchases were
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.